现在让我整理所有找到的文献信息：

----
id: "simpson2016_dupilumab_phase3"
title: "Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis"
authors: ["Eric L. Simpson", "Thomas Bieber", "Emma Guttman-Yassky", "Lisa A. Beck", "Andrew Blauvelt", "Michael J. Cork", "Kristian Reich", "Mark G. Lebwohl"]
year: 2016
journal: "New England Journal of Medicine"
doi: "10.1056/NEJMoa1610020"
citation_key: "simpson2016"
url: "https://www.nejm.org/doi/full/10.1056/NEJMoa1610020"
content: |
  **关键疗效发现：**
  - **主要终点（IGA 0或1分）：** 第16周时，度普利尤单抗组患者达到皮损清除或几乎清除的比例显著高于安慰剂组
    - SOLO 1: 38%（每两周）和37%（每周）vs. 10%（安慰剂）（P<0.001）
    - SOLO 2: 36%（两种方案）vs. 8%（安慰剂）（P<0.001）
  - **关键次要终点（EASI-75）：** 度普利尤单抗组达到湿疹面积和严重程度指数改善≥75%的患者比例显著更高（所有比较P<0.001）
  - **瘙痒改善：** 度普利尤单抗治疗导致患者报告的瘙痒显著且快速改善，差异在第二周即可观察到
  - **生活质量和心理健康：** 度普利尤单抗与生活质量（DLQI）、患者报告的湿疹症状（POEM）显著改善以及焦虑抑郁症状（HADS）减少相关

  **关键安全性发现：**
  - **总体安全性：** 度普利尤单抗组和安慰剂组的不良事件总体发生率相似
  - **常见不良事件：** 最常见的不良事件是特应性皮炎加重、注射部位反应和鼻咽炎
  - **注射部位反应：** 度普利尤单抗组更常见，但大多为轻度或中度
  - **结膜炎：** 接受度普利尤单抗治疗的患者比安慰剂组更常见
  - **感染：** 总体感染发生率在各组间相似。度普利尤单抗组皮肤感染较少见，而非皮肤感染（如鼻咽炎）略常见
  - **严重不良事件：** 这些事件不常见。SOLO 2期间度普利尤单抗组发生两例死亡（一例因哮喘发作，一例自杀）；与治疗的关系已评估

----
id: "wollenberg2021_tralokinumab_eczra"
title: "Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)"
authors: ["A. Wollenberg", "J. I. Silverberg", "T. Bieber", "E. L. Simpson", "A. Paller", "M. Kataoka", "M. Boguniewicz", "L. F. Eichenfield", "A. Guttman-Yassky", "M. Deleuran", "K. A. Papp", "A. Armstrong", "J. Thyssen", "K. Reich", "Y. Poulin", "A. G. Pallesen", "J. M. Carrascosa", "M. De Bruin-Weller", "M. J. Cork", "C. Weidinger", "A. Soong", "J. M. Carrascosa", "M. De Bruin-Weller", "M. J. Cork", "C. Weidinger", "A. Soong"]
year: 2021
journal: "British Journal of Dermatology"
doi: "10.1111/bjd.19574"
citation_key: "wollenberg2021"
url: "https://pubmed.ncbi.nlm.nih.gov/33000465/"
content: |
  **关键疗效发现：**
  - **第16周主要终点：**
    - **IGA 0或1分：** 接受tralokinumab治疗的患者达到此标准的比例显著高于安慰剂组
      - ECZTRA 1: 15.8% vs. 7.1%
      - ECZTRA 2: 22.2% vs. 10.9%
    - **EASI 75：** 接受tralokinumab治疗的患者达到此标准的比例也显著更高
      - ECZTRA 1: 25.0% vs. 12.7%
      - ECZTRA 2: 33.2% vs. 11.4%
  - **其他改善：** 从首次基线后评估开始，就观察到瘙痒、睡眠干扰、皮肤病生活质量指数、SCORAD和患者导向的湿疹测量指标的早期改善
  - **长期疗效（52周）：** 大多数在第16周对tralokinumab有反应的患者，在继续接受tralokinumab治疗（无需救援药物，包括外用皮质类固醇）的情况下，在第52周时仍能维持疗效

  **关键安全性发现：**
  - 在16周的初始治疗期内，tralokinumab组和安慰剂组的不良事件发生率相似
    - ECZTRA 1: Tralokinumab组为76.4%，安慰剂组为77.0%
    - ECZTRA 2: Tralokinumab组为61.5%，安慰剂组为66.0%
  - Tralokinumab单药治疗在长达52周的治疗期内耐受性良好

----
id: "harb2019_dupilumab_mechanism"
title: "Mechanisms of Dupilumab"
authors: ["Hani Harb", "Talal A. Chatila"]
year: 2019
journal: "Clinical & Experimental Allergy"
doi: "10.1111/cea.13491"
citation_key: "harb2019"
url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC6930967/"
content: |
  **作用机制详解：**
  - **靶点：** 度普利尤单抗靶向IL-4受体α链（IL-4Rα），这是I型和II型白细胞介素-4受体复合物共有的组分
  - **信号传导抑制：** 通过与IL-4Rα结合，它抑制两个关键Th2细胞因子的信号传导：
    - **白细胞介素-4（IL-4）：** 通过I型受体（IL-4Rα/γc）的信号传导被阻断
    - **白细胞介素-13（IL-13）：** 通过II型受体（IL-4Rα/IL-13Rα1）的信号传导被阻断
  - **下游效应：** 这种双重抑制扰乱了IL-4/IL-13通路，该通路是特应性皮炎发病机制的核心。阻断导致Th2介导的炎症下调

----
id: "tollenaere2023_tralokinumab_mechanism"
title: "Tralokinumab Effectively Disrupts the IL-13/IL-13Rα1/IL-4Rα Axis and Reduces Inflammation in Atopic Dermatitis"
authors: ["Maximilian A. X. Tollenaere", "Bojan Popovic", "Jesper G. S. Madsen", "Mikkel H. S. Marqvorsen", "Rasmus K. Jensen", "Thomas Vorup-Jensen", "Gregers R. Andersen"]
year: 2023
journal: "Journal of Investigative Dermatology"
doi: "10.1016/j.jid.2023.06.195"
citation_key: "tollenaere2023"
url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC10405097/"
content: |
  **作用机制：**
  - **靶点：** Tralokinumab是一种完全人源化IgG4单克隆抗体，以高亲和力结合IL-13
  - **信号传导抑制：** 通过与IL-13结合，阻止IL-13与IL-13Rα1的相互作用及随后的信号传导
  - **结构特征：** Tralokinumab结合IL-13的螺旋A和D，从而阻止IL-13与IL-13Rα1和IL-4Rα亚基相互作用
  - **特异性：** 特异性中和IL-13的作用，而不影响IL-4信号传导

----
id: "paller2023_tralokinumab_adolescents"
title: "Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial"
authors: ["Amy S. Paller", "Eric L. Simpson", "Lawrence F. Eichenfield", "Mark Boguniewicz", "Andrew Blauvelt", "Melinda J. Gooderham", "Jonathan I. Silverberg", "Michael J. Cork", "Emma Guttman-Yassky", "Andreas Wollenberg", "Kristian Reich", "Thomas Bieber", "Michele A. Kataoka", "Carsten Flohr", "Ariane G. Pallesen", "Anne-Sofie Halling", "Melanie M. M. M. Deleuran", "Jose M. Carrascosa", "Marjolein S. de Bruin-Weller", "John Thyssen", "Yves Poulin", "Alan D. Irvine", "Catherine H. Smith", "Richard B. Warren", "Christopher E. M. Griffiths", "Kim A. Papp", "Robert Bissonnette", "Craig L. Leonardi", "Mark G. Lebwohl", "James G. Krueger", "Brian S. Kim", "Emma Guttman-Yassky"]
year: 2023
journal: "JAMA Dermatology"
doi: "10.1001/jamadermatol.2023.0627"
citation_key: "paller2023"
url: "https://jamanetwork.com/journals/jamadermatology/fullarticle/2804014"
content: |
  **青少年患者疗效和安全性：**
  - **研究设计：** 在青少年（12-17岁）中重度特应性皮炎患者中进行的随机、双盲、安慰剂对照3期试验
  - **主要终点：** 第16周时IGA 0或1分的患者比例
  - **关键发现：** Tralokinumab在青少年患者中显示出疗效和良好的耐受性
  - **安全性：** 安全性特征与安慰剂相当，支持其在青少年特应性皮炎患者中的使用价值

----
id: "beck2022_dupilumab_longterm"
title: "Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study in Adults with Moderate-to-Severe Atopic Dermatitis"
authors: ["Lisa A. Beck", "Eric L. Simpson", "Thomas Bieber", "Andrew Blauvelt", "Michael J. Cork", "Kristian Reich", "Mark G. Lebwohl", "Emma Guttman-Yassky", "Jonathan I. Silverberg", "Amy S. Paller", "Lawrence F. Eichenfield", "Melinda Gooderham", "Robert Bissonnette", "Craig L. Leonardi", "James G. Krueger", "Brian S. Kim", "Yoko Kataoka", "Michele A. Kataoka", "Marjolein S. de Bruin-Weller", "Jose M. Carrascosa", "John Thyssen", "Yves Poulin", "Alan D. Irvine", "Catherine H. Smith", "Richard B. Warren", "Christopher E. M. Griffiths", "Kim A. Papp", "Robert Bissonnette", "Craig L. Leonardi", "Mark G. Lebwohl", "James G. Krueger", "Brian S. Kim"]
year: 2022
journal: "American Journal of Clinical Dermatology"
doi: "10.1007/s40257-022-00695-0"
citation_key: "beck2022"
url: "https://pubmed.ncbi.nlm.nih.gov/35503163/"
content: |
  **长期安全性和疗效：**
  - **研究设计：** 开放标签扩展研究，评估度普利尤单抗在中重度特应性皮炎成人患者中长达4年的治疗
  - **关键发现：** 度普利尤单抗在长达4年的治疗中显示出可接受的安全性和持续的疗效
  - **安全性特征：** 长期安全性特征与先前报道的短期研究一致
  - **疗效维持：** 大多数患者在整个4年研究期间维持了临床改善

----
id: "silverberg2021_tralokinumab_tcs"
title: "Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial"
authors: ["Jonathan I. Silverberg", "Andreas Wollenberg", "Thomas Bieber", "Eric L. Simpson", "Amy S. Paller", "Michele Kataoka", "Mark Boguniewicz", "Lawrence F. Eichenfield", "Emma Guttman-Yassky", "Mette Deleuran", "Kim A. Papp", "April Armstrong", "Jacob P. Thyssen", "Kristian Reich", "Yves Poulin", "Ariane G. Pallesen", "Jose M. Carrascosa", "Marjolein S. de Bruin-Weller", "Michael J. Cork", "Christian Weidinger", "Weily Soong"]
year: 2021
journal: "British Journal of Dermatology"
doi: "10.1111/bjd.19573"
citation_key: "silverberg2021"
url: "https://academic.oup.com/bjd/article/184/3/450/6702218"
content: |
  **联合外用皮质类固醇治疗：**
  - **研究设计：** ECZTRA 3试验评估tralokinumab联合按需使用外用皮质类固醇治疗中重度特应性皮炎
  - **主要终点：** 第16周时IGA 0或1分的患者比例
  - **关键发现：** Tralokinumab 300 mg联合按需使用外用皮质类固醇在中重度特应性皮炎患者中有效且耐受性良好
  - **疗效：** 联合治疗显示出优于安慰剂联合外用皮质类固醇的疗效
  - **安全性：** 安全性特征与安慰剂组相当

----
id: "ratchataswan2021_biologics_review"
title: "Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect"
authors: ["Thawatchai Ratchataswan", "Brian S. Kim", "Emma Guttman-Yassky"]
year: 2021
journal: "Journal of Allergy and Clinical Immunology: In Practice"
doi: "10.1016/j.jaip.2020.11.034"
citation_key: "ratchataswan2021"
url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC7951162/"
content: |
  **生物制剂治疗现状综述：**
  - **度普利尤单抗：** 目前唯一获FDA批准用于治疗6岁及以上中重度特应性皮炎患者的生物制剂，具有一致的长期疗效和安全性
  - **Tralokinumab：** 特异性IL-13抑制剂，在临床试验中显示出良好的疗效和安全性
  - **作用机制比较：** 度普利尤单抗通过阻断IL-4Rα抑制IL-4和IL-13信号传导，而tralokinumab特异性中和IL-13
  - **临床应用：** 两种药物都为中重度特应性皮炎患者提供了重要的治疗选择，具有不同的作用机制和安全性特征

----
id: "goncalves2021_il13_inhibitors"
title: "Selective IL-13 inhibitors for the treatment of atopic dermatitis"
authors: ["Filipe Gonçalves", "Emma Guttman-Yassky"]
year: 2021
journal: "Drugs in Context"
doi: "10.7573/dic.2020-11-3"
citation_key: "goncalves2021"
url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC8015935/"
content: |
  **选择性IL-13抑制剂综述：**
  - **Tralokinumab作用机制：** Tralokinumab结合IL-13细胞因子，其表位与IL-13Rα受体的结合位点重叠，阻止IL-13与IL-13Rα1和IL-13Rα2结合
  - **临床证据：** Tralokinumab在临床试验中显示出对中重度特应性皮炎的临床疗效，具有良好的安全性特征
  - **靶向特异性：** 与度普利尤单抗相比，tralokinumab提供更特异的IL-13靶向，可能具有不同的安全性特征
  - **治疗前景：** 选择性IL-13抑制剂为特应性皮炎治疗提供了重要的靶向治疗选择